This is one of those stories I could not put on Facebook or TikTok. I am making this free to everyone, if you want to support my journalism I encourage you if you can to become a subscriber. Info below.
In a groundbreaking study orchestrated by the Global COVID Vaccine Safety (GCoVS) Project under the Global Vaccine Data Network™ (GVDN®), researchers embarked on a mission to meticulously scrutinize the safety of COVID-19 vaccines across a vast cohort spanning eight countries.
The study delved into the incidences of adverse events of special interest (AESI) following vaccination, using a harmonized protocol to juxtapose observed rates against historical expectations based on pre-pandemic data.
The colossal endeavor included data from an impressive 99 million vaccinated individuals, tracking the safety profile of three major vaccines: the mRNA-based BNT162b2 and mRNA-1273, alongside the adenovirus-vector ChAdOx1. In total, over 242 million doses were administered, allowing for a detailed analysis of AESI occurrences within a 42-day post-vaccination window.
Click here to read the entire study.
Notably, the study illuminated increased risks for Guillain-Barré syndrome and cerebral venous sinus thrombosis following the ChAdOx1 vaccine's first dose, along with a heightened risk of acute disseminated encephalomyelitis after the initial mRNA-1273 dose.
Furthermore, significant upticks in myocarditis and pericarditis cases were observed across the board, reinforcing previously identified safety concerns.
The research stands as a testament to the international scientific community's commitment to vaccine safety, providing invaluable insights that bolster our understanding of these rare but impactful adverse events.
While confirming known risks, the study also sets the stage for further investigations, ensuring the continued safety and efficacy of COVID-19 vaccination efforts worldwide.
